Research

Hormonal

GLP-1 receptor agonists (GLP-1RA) and dual GLP-1/GIP agonists (e.g., semaglutide, tirzepatide) produce significant weight loss (up to 24.2%) and improve metabolic parameters, but they significantly increase the risk of delayed gastric emptying and perioperative pulmonary aspiration.

If you take semaglutide or tirzepatide, tell your anesthesiologist. These drugs slow down your stomach, which increases the risk of vomiting and inhaling stomach contents during surgery, even if you feel fine. You may need to stop the drug a week before surgery, or your procedure might be delayed. Do not assume standard fasting rules are enough.

GoodQualifiesHIGH confidence
Semaglutide had shown a significant reduction in MACE... The FLOW trial... showed a significant effect in slowing the progress of CKD... GLP-1 agonists are known to enhance gastroparesis, and there are legitimate concerns for aspiration during the induction of general anaesthesia.
Taylor E. Browning et al. · 2025

Why this rating

Based on multiple RCTs (SURMOUNT-1, SURPASS-2, SUSTAIN, FLOW) and systematic reviews cited in the narrative.

Source

The widespread adoption of glucagon-like peptide-1 receptor agonists in the management of obesity and its implications for the anaesthesiologist and intensivist: A narrative review

Taylor E. Browning et al. · 2025

DOI 10.25259/peak_19_2024

narrative_review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →